Fausto Petrelli1, Michele Ghidini2, Mary Cabiddu3, Ezio Pezzica4, Daniela Corti4, Luca Turati5, Antonio Costanzo5, Antonio Varricchio5, Antonio Ghidini6, Sandro Barni3, Gianluca Tomasello7. 1. Oncology Unit, ASST Bergamo Ovest, Treviglio, Italy faupe@libero.it. 2. Medical Oncology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy. 3. Oncology Unit, ASST Bergamo Ovest, Treviglio, Italy. 4. Pathology Unit, ASST Bergamo Ovest, Treviglio, Italy. 5. Surgical Oncology Unit, ASST Bergamo Ovest, Treviglio, Italy. 6. Casa di Cura Igea, Oncology Unit, Milan, Italy. 7. Oncology Unit, Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy.
Abstract
BACKGROUND/AIM: About 15-20% of colorectal cancers (CRCs) have deficiency in a mismatch repair (MMR) protein. MMR has a high level of microsatellite instability (MSI-H). We have conducted this review and meta-analysis to determine the prognostic role of MSI-H status in stage II CRC. MATERIALS AND METHODS: We searched PubMed, EMBASE, The Cochrane Library, Web of Science, and SCOPUS for studies reporting data on overall survival (OS) and disease-free or relapse-free survival (DFS or RFS) for MSI-H compared to microsatellite stable (MSS) CRC. RESULTS: A total of 39 studies were analysed, including 12,110 patients. MSI-H status was associated with a significantly reduced risk of death (HR=0.64, 95%CI=0.52-0.8, p<0.01) and relapse (HR=0.59, 95%CI=0.45-0.77, p<0.01) in stage II CRC. CONCLUSION: MSI-H represents an important prognostic determinant in stage II CRC and may be considered when estimating the risk of recurrence in stage II CRC. Copyright
BACKGROUND/AIM: About 15-20% of colorectal cancers (CRCs) have deficiency in a mismatch repair (MMR) protein. MMR has a high level of microsatellite instability (MSI-H). We have conducted this review and meta-analysis to determine the prognostic role of MSI-H status in stage II CRC. MATERIALS AND METHODS: We searched PubMed, EMBASE, The Cochrane Library, Web of Science, and SCOPUS for studies reporting data on overall survival (OS) and disease-free or relapse-free survival (DFS or RFS) for MSI-H compared to microsatellite stable (MSS) CRC. RESULTS: A total of 39 studies were analysed, including 12,110 patients. MSI-H status was associated with a significantly reduced risk of death (HR=0.64, 95%CI=0.52-0.8, p<0.01) and relapse (HR=0.59, 95%CI=0.45-0.77, p<0.01) in stage II CRC. CONCLUSION:MSI-H represents an important prognostic determinant in stage II CRC and may be considered when estimating the risk of recurrence in stage II CRC. Copyright
Authors: M Pötzsch; E Berg; M Hummel; U Stein; M von Winterfeld; K Jöhrens; B Rau; S Daum; C Treese Journal: Oncoimmunology Date: 2020-09-30 Impact factor: 8.110